Header Logo

Connection

JORGE CASTILLO to Humans

Back to Details
This is a "connection" page, showing publications JORGE CASTILLO has written about Humans.
JORGE CASTILLO
Connection Strength
2.577
Humans
  1. Current and emerging treatment perspectives for adults with Waldenstr?m macroglobulinemia. Expert Rev Anticancer Ther. 2025 May; 25(5):485-497.
    View in: PubMed
    Score: 0.027
  2. Zanubrutinib for the treatment of Bing-Neel syndrome. Br J Haematol. 2025 Apr; 206(4):1136-1140.
    View in: PubMed
    Score: 0.026
  3. Follicular Lymphoma in Chile in the Adult Public Cancer Program: The Impact of Chemoimmunotherapy. Cancer Rep (Hoboken). 2024 Sep; 7(9):e2126.
    View in: PubMed
    Score: 0.025
  4. EBV-positive diffuse large B-cell lymphoma, not otherwise specified: 2024 update on the diagnosis, risk-stratification, and management. Am J Hematol. 2024 Oct; 99(10):2002-2015.
    View in: PubMed
    Score: 0.025
  5. Plasmablastic lymphoma: 2024 update on diagnosis, risk stratification, and management. Am J Hematol. 2024 08; 99(8):1586-1594.
    View in: PubMed
    Score: 0.025
  6. Optimizing BTK Inhibition in Waldenstr?m Macroglobulinemia. J Natl Compr Canc Netw. 2024 05; 22(4).
    View in: PubMed
    Score: 0.025
  7. Waldenstr?m Macroglobulinemia: Targeted Agents Taking Center Stage. Drugs. 2024 Jan; 84(1):17-25.
    View in: PubMed
    Score: 0.024
  8. Does Bortezomib-Dexamethasone-Rituximab-Cyclophosphamide Play a Role in the Treatment of Waldenstr?m's Macroglobulinemia? J Clin Oncol. 2023 08 20; 41(24):4059-4060.
    View in: PubMed
    Score: 0.023
  9. Waldenstr?m Macroglobulinemia: A Myriad of Effective Treatment Options, but Still Work to be Done. Hematol Oncol Clin North Am. 2023 08; 37(4):xiii-xiv.
    View in: PubMed
    Score: 0.023
  10. Novel Agents in Waldenstr?m Macroglobulinemia. Hematol Oncol Clin North Am. 2023 08; 37(4):751-760.
    View in: PubMed
    Score: 0.023
  11. Dose reductions in patients with Waldenstr?m macroglobulinaemia treated with ibrutinib. Br J Haematol. 2023 06; 201(5):897-904.
    View in: PubMed
    Score: 0.023
  12. Bruton tyrosine kinase inhibitors in the management of Waldenstr?m macroglobulinemia. Am J Hematol. 2023 02; 98(2):338-347.
    View in: PubMed
    Score: 0.023
  13. Outcomes of patients with limited-stage plasmablastic lymphoma: A multi-institutional retrospective study. Am J Hematol. 2023 02; 98(2):300-308.
    View in: PubMed
    Score: 0.023
  14. Diffuse Large B-Cell Lymphoma in Chile: The Impact of Combined CHOP Plus Rituximab in the Public Health System. JCO Glob Oncol. 2022 11; 8:e2200165.
    View in: PubMed
    Score: 0.022
  15. EBV-positive diffuse large B-cell lymphoma, not otherwise specified: 2022 update on diagnosis, risk-stratification, and management. Am J Hematol. 2022 07; 97(7):951-965.
    View in: PubMed
    Score: 0.022
  16. Natural history of Waldenstr?m macroglobulinemia following acquired resistance to ibrutinib monotherapy. Haematologica. 2022 05 01; 107(5):1163-1171.
    View in: PubMed
    Score: 0.022
  17. Zanubrutinib for the treatment of adults with Waldenstrom macroglobulinemia. Expert Rev Anticancer Ther. 2022 05; 22(5):471-478.
    View in: PubMed
    Score: 0.022
  18. SOHO State of the Art Updates and Next Questions: Targeted therapies and emerging novel treatment approaches for Waldenstr?m Macroglobulinemia. Clin Lymphoma Myeloma Leuk. 2022 08; 22(8):547-556.
    View in: PubMed
    Score: 0.021
  19. A British view on the management of Waldenstr?m macroglobulinemia. Br J Haematol. 2022 04; 197(2):133-134.
    View in: PubMed
    Score: 0.021
  20. How to Sequence Therapies in Waldenstr?m Macroglobulinemia. Curr Treat Options Oncol. 2021 08 23; 22(10):92.
    View in: PubMed
    Score: 0.021
  21. Complete response to pembrolizumab and radiation in a patient with HIV-negative, EBV-positive plasmablastic lymphoma. Am J Hematol. 2021 10 01; 96(10):E390-E392.
    View in: PubMed
    Score: 0.021
  22. Anaplastic lymphoma kinase-positive large B-cell lymphoma (ALK?+?LBCL): a systematic review of clinicopathological features and management. Leuk Lymphoma. 2021 12; 62(12):2845-2853.
    View in: PubMed
    Score: 0.020
  23. Prognostic value of disease risk score versus gait speed in older adults with lymphoma. Leuk Lymphoma. 2021 12; 62(12):2882-2889.
    View in: PubMed
    Score: 0.020
  24. The evaluation and management of monoclonal gammopathy of renal significance and monoclonal gammopathy of neurological significance. Am J Hematol. 2021 07 01; 96(7):846-853.
    View in: PubMed
    Score: 0.020
  25. Reducing treatment toxicity in Waldenstr?m macroglobulinemia. Expert Opin Drug Saf. 2021 Jun; 20(6):669-676.
    View in: PubMed
    Score: 0.020
  26. Clinical application of genomics in Waldenstr?m macroglobulinemia. Leuk Lymphoma. 2021 08; 62(8):1805-1815.
    View in: PubMed
    Score: 0.020
  27. Management of Waldenstr?m macroglobulinemia in 2020. Hematology Am Soc Hematol Educ Program. 2020 12 04; 2020(1):372-379.
    View in: PubMed
    Score: 0.020
  28. Long-Term Follow-Up of Ibrutinib Monotherapy in Symptomatic, Previously Treated Patients With Waldenstr?m Macroglobulinemia. J Clin Oncol. 2021 02 20; 39(6):565-575.
    View in: PubMed
    Score: 0.019
  29. Ixazomib, dexamethasone, and rituximab in treatment-naive patients with Waldenstr?m macroglobulinemia: long-term follow-up. Blood Adv. 2020 08 25; 4(16):3952-3959.
    View in: PubMed
    Score: 0.019
  30. EBV-positive diffuse large B-cell lymphoma, not otherwise specified: 2020 update on diagnosis, risk-stratification and management. Am J Hematol. 2020 04; 95(4):435-445.
    View in: PubMed
    Score: 0.019
  31. Genomic Landscape of Waldenstr?m Macroglobulinemia and Its Impact on Treatment Strategies. J Clin Oncol. 2020 04 10; 38(11):1198-1208.
    View in: PubMed
    Score: 0.019
  32. A matched case-control study comparing features, treatment and outcomes between patients with non-IgM lymphoplasmacytic lymphoma and Waldenstr?m macroglobulinemia. Leuk Lymphoma. 2020 06; 61(6):1388-1394.
    View in: PubMed
    Score: 0.019
  33. CXCR4 mutational status does not impact outcomes in patients with Waldenstr?m macroglobulinemia treated with proteasome inhibitors. Am J Hematol. 2020 04; 95(4):E95-E98.
    View in: PubMed
    Score: 0.019
  34. Deepening of response after completing rituximab-containing therapy in patients with Waldenstrom macroglobulinemia. Am J Hematol. 2020 04; 95(4):372-378.
    View in: PubMed
    Score: 0.018
  35. Outcomes of bendamustine- or cyclophosphamide-based first-line chemotherapy in older patients with indolent B-cell lymphoma. Am J Hematol. 2020 04; 95(4):354-361.
    View in: PubMed
    Score: 0.018
  36. What is new in the treatment of Waldenstrom macroglobulinemia? Leukemia. 2019 11; 33(11):2555-2562.
    View in: PubMed
    Score: 0.018
  37. How we manage Bing-Neel syndrome. Br J Haematol. 2019 11; 187(3):277-285.
    View in: PubMed
    Score: 0.018
  38. HOLA! from Latin America to the myeloma world. Br J Haematol. 2020 02; 188(3):349-350.
    View in: PubMed
    Score: 0.018
  39. CXCR4 mutation subtypes impact response and survival outcomes in patients with Waldenstr?m macroglobulinaemia treated with ibrutinib. Br J Haematol. 2019 11; 187(3):356-363.
    View in: PubMed
    Score: 0.018
  40. Lymphoplasmacytic Lymphoma and Marginal Zone Lymphoma. Hematol Oncol Clin North Am. 2019 08; 33(4):639-656.
    View in: PubMed
    Score: 0.018
  41. Ibrutinib and Rituximab in Waldenstr?m's Macroglobulinemia. N Engl J Med. 2018 11 15; 379(20):1973-4.
    View in: PubMed
    Score: 0.017
  42. Long survival in patients with Waldenstr?m macroglobulinaemia diagnosed at a young age. Br J Haematol. 2019 05; 185(4):799-802.
    View in: PubMed
    Score: 0.017
  43. Ibrutinib Monotherapy in Symptomatic, Treatment-Na?ve Patients With Waldenstr?m Macroglobulinemia. J Clin Oncol. 2018 09 20; 36(27):2755-2761.
    View in: PubMed
    Score: 0.017
  44. Genomic Landscape of Waldenstr?m Macroglobulinemia. Hematol Oncol Clin North Am. 2018 10; 32(5):745-752.
    View in: PubMed
    Score: 0.017
  45. Initial Evaluation of the Patient with Waldenstr?m Macroglobulinemia. Hematol Oncol Clin North Am. 2018 10; 32(5):811-820.
    View in: PubMed
    Score: 0.017
  46. The real world of Waldenstr?m's macroglobulinaemia. Lancet Haematol. 2018 07; 5(7):e275-e276.
    View in: PubMed
    Score: 0.017
  47. EBV-positive diffuse large B-cell lymphoma, not otherwise specified: 2018 update on diagnosis, risk-stratification and management. Am J Hematol. 2018 07; 93(7):953-962.
    View in: PubMed
    Score: 0.017
  48. Viral lymphomagenesis: beyond the usual suspects. Br J Haematol. 2018 09; 182(5):617-618.
    View in: PubMed
    Score: 0.017
  49. Impact of ibrutinib dose intensity on patient outcomes in previously treated Waldenstr?m macroglobulinemia. Haematologica. 2018 10; 103(10):e466-e468.
    View in: PubMed
    Score: 0.016
  50. Fitting mSMART Into the Current Clinical Management of Waldenstr?m Macroglobulinemia. JAMA Oncol. 2018 05 01; 4(5):744-745.
    View in: PubMed
    Score: 0.016
  51. Low levels of von Willebrand markers associate with high serum IgM levels and improve with response to therapy, in patients with Waldenstr?m macroglobulinaemia. Br J Haematol. 2019 03; 184(6):1011-1014.
    View in: PubMed
    Score: 0.016
  52. Bortezomib plus EPOCH is effective as frontline treatment in patients with plasmablastic lymphoma. Br J Haematol. 2019 02; 184(4):679-682.
    View in: PubMed
    Score: 0.016
  53. The neutrophil-lymphocyte ratio is prognostic in patients with early stage aggressive peripheral T cell lymphoma. Br J Haematol. 2019 02; 184(4):650-653.
    View in: PubMed
    Score: 0.016
  54. Response and survival for primary therapy combination regimens and maintenance rituximab in Waldenstr?m macroglobulinaemia. Br J Haematol. 2018 04; 181(1):77-85.
    View in: PubMed
    Score: 0.016
  55. Ibrutinib withdrawal symptoms in patients with Waldenstr?m macroglobulinemia. Haematologica. 2018 07; 103(7):e307-e310.
    View in: PubMed
    Score: 0.016
  56. Ibrutinib discontinuation in Waldenstr?m macroglobulinemia: Etiologies, outcomes, and IgM rebound. Am J Hematol. 2018 08; 93(4):511-517.
    View in: PubMed
    Score: 0.016
  57. Comparing apples to oranges: A commentary on the Mayo study of MYD88 significance in Waldenstrom's macroglobulinemia. Am J Hematol. 2018 03; 93(3):E69-E71.
    View in: PubMed
    Score: 0.016
  58. Toward personalized treatment in Waldenstr?m macroglobulinemia. Hematology Am Soc Hematol Educ Program. 2017 12 08; 2017(1):365-370.
    View in: PubMed
    Score: 0.016
  59. MYD88 wild-type Waldenstrom Macroglobulinaemia: differential diagnosis, risk of histological transformation, and?overall survival. Br J Haematol. 2018 02; 180(3):374-380.
    View in: PubMed
    Score: 0.016
  60. Late infections and secondary malignancies after bendamustine/rituximab or RCHOP/RCVP chemotherapy for B-cell lymphomas. Am J Hematol. 2018 01; 93(1):E1-E3.
    View in: PubMed
    Score: 0.016
  61. Bortezomib in plasmablastic lymphoma: A glimpse of hope for a hard-to-treat disease. Leuk Res. 2017 11; 62:12-16.
    View in: PubMed
    Score: 0.016
  62. Comparative outcomes of immunochemotherapy regimens in Waldenstr?m macroglobulinaemia. Br J Haematol. 2017 10; 179(1):106-115.
    View in: PubMed
    Score: 0.016
  63. Novel approaches to targeting MYD88 in Waldenstr?m macroglobulinemia. Expert Rev Hematol. 2017 08; 10(8):739-744.
    View in: PubMed
    Score: 0.015
  64. IgM myeloma: A multicenter retrospective study of 134 patients. Am J Hematol. 2017 Aug; 92(8):746-751.
    View in: PubMed
    Score: 0.015
  65. Serum IgM level as predictor of symptomatic hyperviscosity in patients with Waldenstr?m macroglobulinaemia. Br J Haematol. 2017 06; 177(5):717-725.
    View in: PubMed
    Score: 0.015
  66. MYD88 mutations can be used to identify malignant pleural effusions in Waldenstr?m macroglobulinaemia. Br J Haematol. 2018 02; 180(4):578-581.
    View in: PubMed
    Score: 0.015
  67. Plasma Cell Disorders. Prim Care. 2016 Dec; 43(4):677-691.
    View in: PubMed
    Score: 0.015
  68. Risk factors for progression from smoldering into active myeloma: additional insights from a population-based study. Eur J Haematol. 2016 Sep; 97(3):217-8.
    View in: PubMed
    Score: 0.015
  69. Risk Factors for Early Death After Rituximab-Based Immunochemotherapy in Older Patients With Diffuse Large B-Cell Lymphoma. J Natl Compr Canc Netw. 2016 09; 14(9):1121-9.
    View in: PubMed
    Score: 0.015
  70. Idelalisib in Waldenstr?m macroglobulinemia: high incidence of hepatotoxicity. Leuk Lymphoma. 2017 04; 58(4):1002-1004.
    View in: PubMed
    Score: 0.015
  71. Secondary malignancies in patients with multiple myeloma, Waldenstr?m macroglobulinemia and monoclonal gammopathy of undetermined significance. Leuk Lymphoma. 2017 04; 58(4):773-780.
    View in: PubMed
    Score: 0.015
  72. "All the soarings of my mind begin in my blood:" central nervous system complication of Waldenstr?m macroglobulinemia. Am J Hematol. 2016 Oct; 91(10):1057-60.
    View in: PubMed
    Score: 0.015
  73. Renal disease related to Waldenstr?m macroglobulinaemia: incidence, pathology and clinical outcomes. Br J Haematol. 2016 Nov; 175(4):623-630.
    View in: PubMed
    Score: 0.015
  74. Histological transformation to diffuse large B-cell lymphoma in patients with Waldenstr?m macroglobulinemia. Am J Hematol. 2016 10; 91(10):1032-5.
    View in: PubMed
    Score: 0.015
  75. Human immunodeficiency virus-associated lymphomas in the antiretroviral therapy era: Analysis of the National Cancer Data Base. Cancer. 2016 09 01; 122(17):2689-97.
    View in: PubMed
    Score: 0.014
  76. Transformation of a previously diagnosed diffuse large B-cell lymphoma to plasmablastic lymphoma. Am J Hematol. 2016 Aug; 91(8):E324.
    View in: PubMed
    Score: 0.014
  77. EBV-positive diffuse large B-cell lymphoma of the elderly: 2016 update on diagnosis, risk-stratification, and management. Am J Hematol. 2016 May; 91(5):529-37.
    View in: PubMed
    Score: 0.014
  78. Atrial fibrillation associated with ibrutinib in Waldenstr?m macroglobulinemia. Am J Hematol. 2016 06; 91(6):E312-3.
    View in: PubMed
    Score: 0.014
  79. Central nervous system involvement by multiple myeloma: A multi-institutional retrospective study of 172 patients in daily clinical practice. Am J Hematol. 2016 06; 91(6):575-80.
    View in: PubMed
    Score: 0.014
  80. Response to ibrutinib in a patient with IgG lymphoplasmacytic lymphoma carrying the MYD88 L265P gene mutation. Leuk Lymphoma. 2016 11; 57(11):2699-701.
    View in: PubMed
    Score: 0.014
  81. Outcomes of HIV-associated Hodgkin lymphoma in the era of antiretroviral therapy. AIDS. 2016 Mar 13; 30(5):787-96.
    View in: PubMed
    Score: 0.014
  82. Survival Claims From Observational Data on Cancer Therapy. J Clin Oncol. 2016 Apr 20; 34(12):1425-7.
    View in: PubMed
    Score: 0.014
  83. Cutaneous involvement in multiple myeloma: a multi-institutional retrospective study of 53 patients. Leuk Lymphoma. 2016 09; 57(9):2071-6.
    View in: PubMed
    Score: 0.014
  84. Inhibition of the Bruton Tyrosine Kinase Pathway in B-Cell Lymphoproliferative Disorders. Cancer J. 2016 Jan-Feb; 22(1):34-9.
    View in: PubMed
    Score: 0.014
  85. Central nervous system involvement by Waldenstr?m macroglobulinaemia (Bing-Neel syndrome): a multi-institutional retrospective study. Br J Haematol. 2016 Mar; 172(5):709-15.
    View in: PubMed
    Score: 0.014
  86. Relationship between obesity and clinical outcome in adults with acute myeloid leukemia: A pooled analysis from four CALGB (alliance) clinical trials. Am J Hematol. 2016 Feb; 91(2):199-204.
    View in: PubMed
    Score: 0.014
  87. Rituximab intolerance in patients with Waldenstr?m macroglobulinaemia. Br J Haematol. 2016 08; 174(4):645-8.
    View in: PubMed
    Score: 0.014
  88. Validation of clinical prognostic indices for diffuse large B-cell lymphoma in the National Cancer Data Base. Cancer Causes Control. 2015 Aug; 26(8):1163-72.
    View in: PubMed
    Score: 0.013
  89. Potential for improved survival with intensification of daunorubicin based induction chemotherapy in acute myeloid leukemia patients who do not receive transplant: A multicenter retrospective study. Leuk Res. 2015 Aug; 39(8):812-7.
    View in: PubMed
    Score: 0.013
  90. CD20-negative diffuse large B-cell lymphoma presenting with lactic acidosis. Am J Hematol. 2015 Mar; 90(3):E49-50.
    View in: PubMed
    Score: 0.013
  91. CD20-negative diffuse large B-cell lymphomas: biology and emerging therapeutic options. Expert Rev Hematol. 2015 Jun; 8(3):343-54.
    View in: PubMed
    Score: 0.013
  92. The biology and treatment of plasmablastic lymphoma. Blood. 2015 Apr 09; 125(15):2323-30.
    View in: PubMed
    Score: 0.013
  93. Bortezomib in combination with infusional dose-adjusted EPOCH for the treatment of plasmablastic lymphoma. Br J Haematol. 2015 May; 169(3):352-5.
    View in: PubMed
    Score: 0.013
  94. Treatment selection and outcomes in early-stage classical Hodgkin lymphoma: analysis of the National Cancer Data Base. J Clin Oncol. 2015 Feb 20; 33(6):625-33.
    View in: PubMed
    Score: 0.013
  95. Biology, prognosis, and therapy of Waldenstr?m Macroglobulinemia. Cancer Treat Res. 2015; 165:177-95.
    View in: PubMed
    Score: 0.013
  96. Overall survival and competing risks of death in patients with?Waldenstr?m macroglobulinaemia: an analysis of the Surveillance, Epidemiology and End Results database. Br J Haematol. 2015 Apr; 169(1):81-9.
    View in: PubMed
    Score: 0.013
  97. Extranodal marginal zone lymphoma from ocular adnexae with subcutaneous involvement. Am J Dermatopathol. 2014 Nov; 36(11):e189-93.
    View in: PubMed
    Score: 0.013
  98. Prognostic factors for advanced-stage human immunodeficiency virus-associated classical Hodgkin lymphoma treated with doxorubicin, bleomycin, vinblastine, and dacarbazine plus combined antiretroviral therapy: a multi-institutional retrospective study. Cancer. 2015 Feb 01; 121(3):423-31.
    View in: PubMed
    Score: 0.013
  99. Waldenstr?m macroglobulinemia. Hematol Oncol Clin North Am. 2014 Oct; 28(5):945-70.
    View in: PubMed
    Score: 0.013
  100. Systemic lupus erythematosus is associated with increased incidence of hematologic malignancies: a meta-analysis of prospective cohort studies. Leuk Res. 2014 Sep; 38(9):1067-71.
    View in: PubMed
    Score: 0.013
  101. Carfilzomib, rituximab, and dexamethasone (CaRD) treatment offers a neuropathy-sparing approach for treating Waldenstr?m's macroglobulinemia. Blood. 2014 Jul 24; 124(4):503-10.
    View in: PubMed
    Score: 0.013
  102. The relation between cigarette smoking and risk of acute myeloid leukemia: an updated meta-analysis of epidemiological studies. Am J Hematol. 2014 Aug; 89(8):E125-32.
    View in: PubMed
    Score: 0.012
  103. Improved survival with rituximab-based chemoimmunotherapy in older patients with extranodal diffuse large B-cell lymphoma. Leuk Res. 2014 Aug; 38(8):866-73.
    View in: PubMed
    Score: 0.012
  104. Ofatumumab as front-line therapy in untreated chronic lymphocytic leukemia. Future Oncol. 2014 May; 10(7):1147-55.
    View in: PubMed
    Score: 0.012
  105. Primary refractory Hodgkin lymphoma: limited options and poor survival--but not always. Am J Hematol. 2014 Aug; 89(8):853-7.
    View in: PubMed
    Score: 0.012
  106. Sites of extranodal involvement are prognostic in patients with diffuse large B-cell lymphoma in the rituximab era: an analysis of the Surveillance, Epidemiology and End Results database. Am J Hematol. 2014 Mar; 89(3):310-4.
    View in: PubMed
    Score: 0.012
  107. Viral lymphomagenesis: from pathophysiology to the rationale for novel therapies. Br J Haematol. 2014 May; 165(3):300-15.
    View in: PubMed
    Score: 0.012
  108. Obesity is associated with increased relative risk of diffuse large B-cell lymphoma: a meta-analysis of observational studies. Clin Lymphoma Myeloma Leuk. 2014 Apr; 14(2):122-30.
    View in: PubMed
    Score: 0.012
  109. Population-based prognostic factors for survival in patients with Burkitt lymphoma: an analysis from the Surveillance, Epidemiology, and End Results database. Cancer. 2013 Oct 15; 119(20):3672-9.
    View in: PubMed
    Score: 0.012
  110. Similar outcomes in Asian and Western patients with diffuse large B-cell lymphoma treated with R-CHOP. Leuk Res. 2013 Apr; 37(4):386-91.
    View in: PubMed
    Score: 0.011
  111. Not all aggressive adult T-cell leukemia/lymphoma subtypes are created equal. J Clin Oncol. 2012 Oct 01; 30(28):3560; author reply 3561.
    View in: PubMed
    Score: 0.011
  112. Survival of patients with marginal zone lymphoma: analysis of the Surveillance, Epidemiology, and End Results database. Cancer. 2013 Feb 01; 119(3):629-38.
    View in: PubMed
    Score: 0.011
  113. Prognosis in primary effusion lymphoma is associated with the number of body cavities involved. Leuk Lymphoma. 2012 Dec; 53(12):2378-82.
    View in: PubMed
    Score: 0.011
  114. Diagnosis and management of hyponatremia in cancer patients. Oncologist. 2012; 17(6):756-65.
    View in: PubMed
    Score: 0.011
  115. No association between cigarette smoking and incidence of plasma cell myeloma: a meta-analysis of 17 observational studies. Am J Hematol. 2012 Jul; 87(7):729-31.
    View in: PubMed
    Score: 0.011
  116. Cigarette smoking is associated with a small increase in the incidence of non-Hodgkin lymphoma: a meta-analysis of 24 observational studies. Leuk Lymphoma. 2012 Oct; 53(10):1911-9.
    View in: PubMed
    Score: 0.011
  117. Human immunodeficiency virus-associated plasmablastic lymphoma: poor prognosis in the era of highly active antiretroviral therapy. Cancer. 2012 Nov 01; 118(21):5270-7.
    View in: PubMed
    Score: 0.011
  118. Increased incidence of non-Hodgkin lymphoma, leukemia, and myeloma in patients with diabetes mellitus type 2: a meta-analysis of observational studies. Blood. 2012 May 24; 119(21):4845-50.
    View in: PubMed
    Score: 0.011
  119. Why is my patient neutropenic? Hematol Oncol Clin North Am. 2012 Apr; 26(2):253-66, vii.
    View in: PubMed
    Score: 0.011
  120. Peripheral T-cell lymphoma with a regulatory T-cell phenotype: report of a nodal and an extranodal case from Peru. Appl Immunohistochem Mol Morphol. 2012 Mar; 20(2):196-200.
    View in: PubMed
    Score: 0.011
  121. PCI-32765: a novel Bruton's tyrosine kinase inhibitor for the treatment of lymphoid malignancies. Expert Opin Investig Drugs. 2012 Mar; 21(3):355-61.
    View in: PubMed
    Score: 0.011
  122. Rituximab in combination with chemotherapy versus chemotherapy alone in HIV-associated non-Hodgkin lymphoma: a pooled analysis of 15 prospective studies. Am J Hematol. 2012 Mar; 87(3):330-3.
    View in: PubMed
    Score: 0.011
  123. Risk factors associated with Clostridium difficile infection in adult oncology patients with a history of recent hospitalization for febrile neutropenia. Leuk Lymphoma. 2012 Aug; 53(8):1617-9.
    View in: PubMed
    Score: 0.011
  124. Obesity but not overweight increases the incidence and mortality of leukemia in adults: a meta-analysis of prospective cohort studies. Leuk Res. 2012 Jul; 36(7):868-75.
    View in: PubMed
    Score: 0.011
  125. The Hans algorithm is not prognostic in patients with diffuse large B-cell lymphoma treated with R-CHOP. Leuk Res. 2012 Apr; 36(4):413-7.
    View in: PubMed
    Score: 0.011
  126. CAL-101: a phosphatidylinositol-3-kinase p110-delta inhibitor for the treatment of lymphoid malignancies. Expert Opin Investig Drugs. 2012 Jan; 21(1):15-22.
    View in: PubMed
    Score: 0.011
  127. Meta-analysis of the association between cigarette smoking and incidence of Hodgkin's Lymphoma. J Clin Oncol. 2011 Oct 10; 29(29):3900-6.
    View in: PubMed
    Score: 0.010
  128. Positive HIV ELISA test, autoimmune hemolytic anemia, and generalized lymphadenopathy: a unifying diagnosis. Am J Hematol. 2011 Aug; 86(8):690-3.
    View in: PubMed
    Score: 0.010
  129. HIV-negative plasmablastic lymphoma: not in the mouth. Clin Lymphoma Myeloma Leuk. 2011 Apr; 11(2):185-9.
    View in: PubMed
    Score: 0.010
  130. Plasmablastic lymphoma: a systematic review. ScientificWorldJournal. 2011 Mar 22; 11:687-96.
    View in: PubMed
    Score: 0.010
  131. Prognostic factors in patients with HIV-associated peripheral T-cell lymphoma: a multicenter study. Am J Hematol. 2011 Mar; 86(3):256-61.
    View in: PubMed
    Score: 0.010
  132. Ofatumumab for newly diagnosed and relapsed/refractory chronic lymphocytic leukemia. Expert Rev Anticancer Ther. 2011 Feb; 11(2):151-60.
    View in: PubMed
    Score: 0.010
  133. Epstein-barr virus-positive diffuse large B-cell lymphoma of the elderly: what we know so far. Oncologist. 2011; 16(1):87-96.
    View in: PubMed
    Score: 0.010
  134. Management of HIV-associated lymphomas. Med Health R I. 2011 Jan; 94(1):4-6.
    View in: PubMed
    Score: 0.010
  135. Clinical and pathological differences between human immunodeficiency virus-positive and human immunodeficiency virus-negative patients with plasmablastic lymphoma. Leuk Lymphoma. 2010 Nov; 51(11):2047-53.
    View in: PubMed
    Score: 0.010
  136. Lymphopenia as a prognostic factor in patients with peripheral T-cell lymphoma, unspecified. Leuk Lymphoma. 2010 Oct; 51(10):1822-8.
    View in: PubMed
    Score: 0.010
  137. Non-AIDS defining cancers. Med Health R I. 2010 Oct; 93(10):296-8.
    View in: PubMed
    Score: 0.010
  138. Association between red blood cell transfusions and development of non-Hodgkin lymphoma: a meta-analysis of observational studies. Blood. 2010 Oct 21; 116(16):2897-907.
    View in: PubMed
    Score: 0.010
  139. Extramedullary relapse of acute myeloid leukemia in a surgical wound. Leuk Lymphoma. 2011 Mar; 52(3):541-3.
    View in: PubMed
    Score: 0.010
  140. Prognostic factors in chemotherapy-treated patients with HIV-associated Plasmablastic lymphoma. Oncologist. 2010; 15(3):293-9.
    View in: PubMed
    Score: 0.009
  141. Depth of Response From Fixed-Duration Treatment Is Associated With Superior Survival in Waldenstrom Macroglobulinemia. Am J Hematol. 2025 Jun; 100(6):980-986.
    View in: PubMed
    Score: 0.007
  142. Real-world data on the clinical features, therapy patterns, and outcomes of older adults with diffuse large B-cell lymphoma in Latin America: A study from the Grupo de Estudio Latinoamericano de Linfoproliferativos (GELL). J Geriatr Oncol. 2025 01; 16(1):102160.
    View in: PubMed
    Score: 0.006
  143. Navigating the changing landscape of BTK-targeted therapies for B cell lymphomas and chronic lymphocytic leukaemia. Nat Rev Clin Oncol. 2024 Dec; 21(12):867-887.
    View in: PubMed
    Score: 0.006
  144. Simplified Risk Stratification Model for Patients With Waldenstr?m Macroglobulinemia. J Clin Oncol. 2024 Jul 20; 42(21):2527-2536.
    View in: PubMed
    Score: 0.006
  145. Biomarker analysis of the ASPEN study comparing zanubrutinib with ibrutinib for patients with Waldenstr?m macroglobulinemia. Blood Adv. 2024 04 09; 8(7):1639-1650.
    View in: PubMed
    Score: 0.006
  146. Lymphoplasmacytic lymphoma and multiple myeloma coexisting in the same patient: a case series and literature review. Leuk Lymphoma. 2024 Jul; 65(7):943-949.
    View in: PubMed
    Score: 0.006
  147. Optimization of Advanced Molecular Genetic Testing Utilization in Hematopathology: A Goldilocks Approach to Bone Marrow Testing. JCO Oncol Pract. 2024 02; 20(2):220-227.
    View in: PubMed
    Score: 0.006
  148. Localized upper extremity edema secondary to Bruton's tyrosine kinase inhibition. Leuk Lymphoma. 2023 12; 64(12):2047-2050.
    View in: PubMed
    Score: 0.006
  149. Zanubrutinib Versus Ibrutinib in Symptomatic Waldenstr?m Macroglobulinemia: Final Analysis From the Randomized Phase III ASPEN Study. J Clin Oncol. 2023 Nov 20; 41(33):5099-5106.
    View in: PubMed
    Score: 0.006
  150. Real-world experience in older patients with diffuse large B-cell lymphoma treated in Latin America: A study by the Latin American study group of lymphoproliferative disorders (GELL). J Geriatr Oncol. 2023 09; 14(7):101565.
    View in: PubMed
    Score: 0.006
  151. The prognostic role of red cell distribution width on all-cause and cause-specific outcomes in peripheral T-cell lymphoma: a retrospective cohort study. Leuk Lymphoma. 2023 Jul-Aug; 64(7):1225-1233.
    View in: PubMed
    Score: 0.006
  152. More Than 2% of Circulating Tumor Plasma Cells Defines Plasma Cell Leukemia-Like Multiple Myeloma. J Clin Oncol. 2023 03 01; 41(7):1383-1392.
    View in: PubMed
    Score: 0.006
  153. Treatment and Survival Outcomes of Waldenstrom Macroglobulinemia in Latin American Patients: A Multinational Retrospective Cohort Study. JCO Glob Oncol. 2022 08; 8:e2100380.
    View in: PubMed
    Score: 0.006
  154. Clonal hematopoiesis is associated with increased risk of progression of asymptomatic Waldenstr?m macroglobulinemia. Blood Adv. 2022 04 12; 6(7):2230-2235.
    View in: PubMed
    Score: 0.005
  155. An international analysis evaluating frontline bendamustine with rituximab in extranodal marginal zone lymphoma. Blood Adv. 2022 04 12; 6(7):2035-2044.
    View in: PubMed
    Score: 0.005
  156. Primary cutaneous Epstein-Barr virus-positive B-cell lymphoid proliferation with features of diffuse large B-cell lymphoma and mucocutaneous ulcer: a diagnostic dilemma. Int J Dermatol. 2023 02; 62(2):e87-e90.
    View in: PubMed
    Score: 0.005
  157. Epidemiology of chronic lymphocytic leukemia in Chilean and Amerindian population in Chile. Leuk Lymphoma. 2022 05; 63(5):1137-1143.
    View in: PubMed
    Score: 0.005
  158. Venetoclax in Previously Treated Waldenstr?m Macroglobulinemia. J Clin Oncol. 2022 01 01; 40(1):63-71.
    View in: PubMed
    Score: 0.005
  159. An international, multicenter, retrospective study on the positive impact of cutaneous involvement on the clinical outcome of adult T-cell leukemia/lymphoma. Leuk Lymphoma. 2022 02; 63(2):315-325.
    View in: PubMed
    Score: 0.005
  160. Long-term follow-up of ibrutinib monotherapy in treatment-naive patients with Waldenstrom macroglobulinemia. Leukemia. 2022 02; 36(2):532-539.
    View in: PubMed
    Score: 0.005
  161. Plasmablastic lymphoma transformation in a patient with Waldenstr?m macroglobulinemia treated with ibrutinib. Br J Haematol. 2021 11; 195(3):466-468.
    View in: PubMed
    Score: 0.005
  162. Real-World Data on Adult T-Cell Leukemia/Lymphoma in Latin America: A Study From the Grupo de Estudio Latinoamericano de Linfoproliferativos. JCO Glob Oncol. 2021 07; 7:1151-1166.
    View in: PubMed
    Score: 0.005
  163. Cell-free DNA analysis for detection of MYD88L265P and CXCR4S338X mutations in Waldenstr?m macroglobulinemia. Am J Hematol. 2021 07 01; 96(7):E250-E253.
    View in: PubMed
    Score: 0.005
  164. Bone marrow involvement and subclonal diversity impairs detection of mutated CXCR4 by diagnostic next-generation sequencing in Waldenstr?m macroglobulinaemia. Br J Haematol. 2021 08; 194(4):730-733.
    View in: PubMed
    Score: 0.005
  165. Clinical, inflammatory and immunohistochemical features in a cohort of Peruvian patients with diffuse large B-cell lymphoma. Leuk Res. 2021 03; 102:106513.
    View in: PubMed
    Score: 0.005
  166. Partial response or better at six?months is prognostic of superior progression-free survival in Waldenstr?m macroglobulinaemia patients treated with ibrutinib. Br J Haematol. 2021 02; 192(3):542-550.
    View in: PubMed
    Score: 0.005
  167. Consensus treatment recommendations from the tenth International Workshop for Waldenstr?m Macroglobulinaemia. Lancet Haematol. 2020 Nov; 7(11):e827-e837.
    View in: PubMed
    Score: 0.005
  168. A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenstr?m macroglobulinemia: the ASPEN study. Blood. 2020 10 29; 136(18):2038-2050.
    View in: PubMed
    Score: 0.005
  169. Comparative genomics of CXCR4MUT and CXCR4WT single cells in Waldenstr?m's macroglobulinemia. Blood Adv. 2020 09 22; 4(18):4550-4553.
    View in: PubMed
    Score: 0.005
  170. Primary refractory multiple myeloma: a real-world experience with 85 cases. Leuk Lymphoma. 2020 12; 61(12):2868-2875.
    View in: PubMed
    Score: 0.005
  171. Clinicopathologic characteristics and survival of patients with primary effusion lymphoma. Leuk Lymphoma. 2020 09; 61(9):2093-2102.
    View in: PubMed
    Score: 0.005
  172. The BTK inhibitor ibrutinib may protect against pulmonary injury in COVID-19-infected patients. Blood. 2020 05 21; 135(21):1912-1915.
    View in: PubMed
    Score: 0.005
  173. A Multi-Institutional Validation of the Prognostic Value of the Neutrophil-to-Lymphocyte Ratio in Patients With Diffuse Large B-Cell Lymphoma: A Study From The Latin American Group of Lymphoproliferative Disorders (GELL). Clin Lymphoma Myeloma Leuk. 2020 10; 20(10):637-646.
    View in: PubMed
    Score: 0.005
  174. Different MAF translocations confer similar prognosis in newly diagnosed multiple myeloma patients. Leuk Lymphoma. 2020 08; 61(8):1885-1893.
    View in: PubMed
    Score: 0.005
  175. A multicenter retrospective study of 223 patients with t(14;16) in multiple myeloma. Am J Hematol. 2020 05; 95(5):503-509.
    View in: PubMed
    Score: 0.005
  176. Genomic evolution of ibrutinib-resistant clones in Waldenstr?m macroglobulinaemia. Br J Haematol. 2020 06; 189(6):1165-1170.
    View in: PubMed
    Score: 0.005
  177. SYK is activated by mutated MYD88 and drives pro-survival signaling in MYD88 driven B-cell lymphomas. Blood Cancer J. 2020 01 31; 10(1):12.
    View in: PubMed
    Score: 0.005
  178. Reply to F.D. Leonard. J Clin Oncol. 2019 10 10; 37(29):2701-2702.
    View in: PubMed
    Score: 0.004
  179. Hematogenous extramedullary relapse in multiple myeloma - a multicenter retrospective study in 127 patients. Am J Hematol. 2019 10; 94(10):1132-1140.
    View in: PubMed
    Score: 0.004
  180. CXCR4 mutations affect presentation and outcomes in patients with Waldenstr?m macroglobulinemia: A systematic review. Expert Rev Hematol. 2019 10; 12(10):873-881.
    View in: PubMed
    Score: 0.004
  181. High Red Cell Distribution Width is an Adverse Predictive and Prognostic Factor in Patients With Diffuse Large B-Cell Lymphoma Treated With Chemoimmunotherapy. Clin Lymphoma Myeloma Leuk. 2019 09; 19(9):e551-e557.
    View in: PubMed
    Score: 0.004
  182. Progression Risk Stratification of Asymptomatic Waldenstr?m Macroglobulinemia. J Clin Oncol. 2019 06 01; 37(16):1403-1411.
    View in: PubMed
    Score: 0.004
  183. Ibrutinib for the treatment of Bing-Neel syndrome: a multicenter study. Blood. 2019 01 24; 133(4):299-305.
    View in: PubMed
    Score: 0.004
  184. Low risk of Pneumocystis jirovecii pneumonia and invasive aspergillosis in patients with Waldenstr?m macroglobulinaemia on ibrutinib. Br J Haematol. 2019 05; 185(4):788-790.
    View in: PubMed
    Score: 0.004
  185. Outcomes of secondary solid tumor malignancies among patients with myeloma: A population-based study. Cancer. 2019 02 15; 125(4):550-558.
    View in: PubMed
    Score: 0.004
  186. Bortezomib overcomes the negative impact of CXCR4 mutations on survival of Waldenstrom macroglobulinemia patients. Blood. 2018 12 13; 132(24):2608-2612.
    View in: PubMed
    Score: 0.004
  187. Profiling of circulating exosomal miRNAs in patients with Waldenstr?m Macroglobulinemia. PLoS One. 2018; 13(10):e0204589.
    View in: PubMed
    Score: 0.004
  188. Waldenstr?m Macroglobulinemia: Lessons Learned from Basic and Clinical Research. Hematol Oncol Clin North Am. 2018 10; 32(5):xiii-xiv.
    View in: PubMed
    Score: 0.004
  189. TP53 mutations are associated with mutated MYD88 and CXCR4, and confer an adverse outcome in Waldenstr?m macroglobulinaemia. Br J Haematol. 2019 01; 184(2):242-245.
    View in: PubMed
    Score: 0.004
  190. Clinical characteristics and treatment outcomes in IgE multiple myeloma: A case-control study. Am J Hematol. 2018 09; 93(9):E238-E241.
    View in: PubMed
    Score: 0.004
  191. Multiple myeloma in patients up to 30?years of age: a multicenter retrospective study of 52 cases. Leuk Lymphoma. 2019 02; 60(2):471-476.
    View in: PubMed
    Score: 0.004
  192. Secondary plasma cell leukemia: a multicenter retrospective study of 101 patients. Leuk Lymphoma. 2019 01; 60(1):118-123.
    View in: PubMed
    Score: 0.004
  193. True, true unrelated? Coexistence of Waldenstr?m macroglobulinemia and cardiac transthyretin amyloidosis. Haematologica. 2018 08; 103(8):e374-e376.
    View in: PubMed
    Score: 0.004
  194. The impact of the neutrophil:lymphocyte ratio in response and survival of patients with de novo diffuse large B-cell lymphoma. Leuk Res. 2018 04; 67:82-85.
    View in: PubMed
    Score: 0.004
  195. Prognostic indicators in primary plasma cell leukaemia: a multicentre retrospective study of 117 patients. Br J Haematol. 2018 03; 180(6):831-839.
    View in: PubMed
    Score: 0.004
  196. Primary cutaneous plasmablastic lymphoma in an immunocompetent patient: is it associated with an indolent course? Leuk Lymphoma. 2018 07; 59(7):1753-1755.
    View in: PubMed
    Score: 0.004
  197. Survival of patients with CD20-negative variants of large B-cell lymphoma: an analysis of the National Cancer Data Base. Leuk Lymphoma. 2018 06; 59(6):1375-1383.
    View in: PubMed
    Score: 0.004
  198. Similar survival outcomes in patients with biclonal versus monoclonal myeloma: a multi-institutional matched case-control study. Ann Hematol. 2017 Oct; 96(10):1693-1698.
    View in: PubMed
    Score: 0.004
  199. Response and survival benefit with chemoimmunotherapy in Epstein-Barr virus-positive diffuse large B-cell lymphoma. Hematol Oncol. 2018 Feb; 36(1):93-97.
    View in: PubMed
    Score: 0.004
  200. Genomics, Signaling, and Treatment of Waldenstr?m Macroglobulinemia. J Clin Oncol. 2017 Mar 20; 35(9):994-1001.
    View in: PubMed
    Score: 0.004
  201. Ibrutinib for patients with rituximab-refractory Waldenstr?m's macroglobulinaemia (iNNOVATE): an open-label substudy of an international, multicentre, phase 3 trial. Lancet Oncol. 2017 Feb; 18(2):241-250.
    View in: PubMed
    Score: 0.004
  202. Prospective, Multicenter Clinical Trial of Everolimus as Primary Therapy in Waldenstrom Macroglobulinemia (WMCTG 09-214). Clin Cancer Res. 2017 May 15; 23(10):2400-2404.
    View in: PubMed
    Score: 0.004
  203. Future therapeutic options for patients with Waldenstr?m macroglobulinemia. Best Pract Res Clin Haematol. 2016 06; 29(2):206-215.
    View in: PubMed
    Score: 0.004
  204. Ibrutinib penetrates the blood brain barrier and shows efficacy in the therapy of Bing Neel syndrome. Br J Haematol. 2017 10; 179(2):339-341.
    View in: PubMed
    Score: 0.004
  205. Recommendations for the diagnosis and initial evaluation of patients with Waldenstr?m Macroglobulinaemia: A Task Force from the 8th International Workshop on Waldenstr?m Macroglobulinaemia. Br J Haematol. 2016 10; 175(1):77-86.
    View in: PubMed
    Score: 0.004
  206. Transcriptome sequencing reveals a profile that corresponds to genomic variants in Waldenstr?m macroglobulinemia. Blood. 2016 08 11; 128(6):827-38.
    View in: PubMed
    Score: 0.004
  207. HCK is a survival determinant transactivated by mutated MYD88, and a direct target of ibrutinib. Blood. 2016 06 23; 127(25):3237-52.
    View in: PubMed
    Score: 0.004
  208. Targeting Myddosome Assembly in Waldenstrom Macroglobulinaemia. Br J Haematol. 2017 06; 177(5):808-813.
    View in: PubMed
    Score: 0.004
  209. To select or not to select? The role of B-cell selection in determining the MYD88 mutation status in Waldenstr?m Macroglobulinaemia. Br J Haematol. 2017 03; 176(5):822-824.
    View in: PubMed
    Score: 0.004
  210. Exome sequencing reveals recurrent germ line variants in patients with familial Waldenstr?m macroglobulinemia. Blood. 2016 05 26; 127(21):2598-606.
    View in: PubMed
    Score: 0.004
  211. Clonal architecture of CXCR4 WHIM-like mutations in Waldenstr?m Macroglobulinaemia. Br J Haematol. 2016 Mar; 172(5):735-44.
    View in: PubMed
    Score: 0.003
  212. The neutrophil-to-lymphocyte ratio is an independent prognostic factor in patients with peripheral T-cell lymphoma, unspecified. Leuk Lymphoma. 2016; 57(1):58-62.
    View in: PubMed
    Score: 0.003
  213. Survival outcomes of secondary cancers in patients with Waldenstr?m macroglobulinemia: An analysis of the SEER database. Am J Hematol. 2015 Aug; 90(8):696-701.
    View in: PubMed
    Score: 0.003
  214. Cyclophosphamide, bortezomib, and dexamethasone combination in waldenstrom macroglobulinemia. Am J Hematol. 2015 Jun; 90(6):E122-3.
    View in: PubMed
    Score: 0.003
  215. Ibrutinib in previously treated Waldenstr?m's macroglobulinemia. N Engl J Med. 2015 Apr 09; 372(15):1430-40.
    View in: PubMed
    Score: 0.003
  216. The BCL2 antagonist ABT-199 triggers apoptosis, and augments ibrutinib and idelalisib mediated cytotoxicity in CXCR4 Wild-type and CXCR4 WHIM mutated Waldenstrom macroglobulinaemia cells. Br J Haematol. 2015 Jul; 170(1):134-8.
    View in: PubMed
    Score: 0.003
  217. Plasma fatty acid profile in multiple myeloma patients. Leuk Res. 2015 Apr; 39(4):400-5.
    View in: PubMed
    Score: 0.003
  218. Extramedullary Waldenstr?m macroglobulinemia. Am J Hematol. 2015 Feb; 90(2):100-4.
    View in: PubMed
    Score: 0.003
  219. CXCR4 WHIM-like frameshift and nonsense mutations promote ibrutinib resistance but do not supplant MYD88(L265P) -directed survival signalling in Waldenstr?m macroglobulinaemia cells. Br J Haematol. 2015 Mar; 168(5):701-7.
    View in: PubMed
    Score: 0.003
  220. Thalidomide for the treatment of hydroa vacciniforme-like lymphoma: report of four pediatric cases from Peru. Am J Hematol. 2014 Dec; 89(12):1160-1.
    View in: PubMed
    Score: 0.003
  221. Large B-cell lymphoma arising in cardiac myxoma or intracardiac fibrinous mass: a localized lymphoma usually associated with Epstein-Barr virus? Cardiovasc Pathol. 2015 Jan-Feb; 24(1):60-4.
    View in: PubMed
    Score: 0.003
  222. Impact of induction regimen and stem cell transplantation on outcomes in double-hit lymphoma: a multicenter retrospective analysis. Blood. 2014 Oct 09; 124(15):2354-61.
    View in: PubMed
    Score: 0.003
  223. Survival trends in Waldenstr?m macroglobulinemia: an analysis of the Surveillance, Epidemiology and End Results database. Blood. 2014 Jun 19; 123(25):3999-4000.
    View in: PubMed
    Score: 0.003
  224. Hematopoietic cell transplantation for plasmablastic lymphoma: a review. Biol Blood Marrow Transplant. 2014 Dec; 20(12):1877-84.
    View in: PubMed
    Score: 0.003
  225. Breast implant-associated anaplastic large-cell lymphoma: long-term follow-up of 60 patients. J Clin Oncol. 2014 Jan 10; 32(2):114-20.
    View in: PubMed
    Score: 0.003
  226. Hepatitis B infection increases the risk of non-Hodgkin lymphoma: a meta-analysis of observational studies. Leuk Res. 2013 Sep; 37(9):1107-15.
    View in: PubMed
    Score: 0.003
  227. Follicular lymphoma with leukemic phase at diagnosis: a series of seven cases and review of the literature. Leuk Res. 2013 Sep; 37(9):1116-9.
    View in: PubMed
    Score: 0.003
  228. Cellular immunotherapy for refractory hematological malignancies. J Transl Med. 2013 Jun 19; 11:150.
    View in: PubMed
    Score: 0.003
  229. Extranodal marginal zone lymphoma of the cranial dura mater: report of three cases and systematic review of the literature. Leuk Lymphoma. 2013 Oct; 54(10):2306-9.
    View in: PubMed
    Score: 0.003
  230. Spontaneous regression of chronic lymphocytic leukemia to a monoclonal B-lymphocytosis or to a normal phenotype. Leuk Lymphoma. 2013 Aug; 54(8):1647-51.
    View in: PubMed
    Score: 0.003
  231. EBV-positive diffuse large b-cell lymphoma in young immunocompetent individuals. Clin Lymphoma Myeloma Leuk. 2011 Dec; 11(6):512-6.
    View in: PubMed
    Score: 0.003
  232. EBV-positive diffuse large B-cell lymphoma of the elderly: a case series from Peru. Am J Hematol. 2011 Aug; 86(8):663-7.
    View in: PubMed
    Score: 0.003
  233. Epstein-Barr virus-positive diffuse large B-cell lymphoma of the elderly treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone: report of two cases from South America. Leuk Lymphoma. 2011 Jan; 52(1):153-6.
    View in: PubMed
    Score: 0.002
  234. Pesticides and non-Hodgkin lymphoma: an overview for the clinician. Med Health R I. 2011 Jan; 94(1):10-2.
    View in: PubMed
    Score: 0.002
  235. Different prognostic factors for survival in acute and lymphomatous adult T-cell leukemia/lymphoma. Leuk Res. 2011 Mar; 35(3):334-9.
    View in: PubMed
    Score: 0.002
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.